Advanced Accelerator Preps Lutetium-Tipped Warhead For NETs Filings
This article was originally published in The Pink Sheet Daily
Executive Summary
France’s Advanced Accelerator Applications is making plans to extend its business to the US after its lead radiotherapeutic, a lutetium labelled somatostatin analog, met its primary endpoint in a Phase III study.